Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting.

Abstract

BACKGROUND:

Pemetrexed maintenance therapy offers a survival benefit in patients with nonprogressive advanced nonsquamous non-small cell lung cancer (NSCLC) with good tolerability. This study was designed to analyze the efficacy and safety of pemetrexed maintenance chemotherapy in advanced nonsquamous NSCLC patients in a real-world setting.

METHODS:

The response rate (RR) and adverse events in 71 nonsquamous NSCLC patients treated with pemetrexed-based chemotherapy were observed until disease progression or unacceptable toxicities. Measures of survival were analyzed during follow-up.

RESULTS:

Of 69 efficacy-evaluable patients, the objective response rate (ORR) was 46.4% and the disease control rate (DCR) was 98.6%. ORR showed no significant difference between patients who received pemetrexed as first-line therapy and those who received pemetrexed as second-line or higher treatment. The median treatment cycle for all patients was 8. The median progression-free survival (PFS) was 9.5 months (m) and median overall survival (OS) was 30.5 m. The univariate and multivariate analyses showed that the number of chemotherapy cycles was an independent factor for PFS. The most common adverse reactions were grade 1 to 2 hematologic toxicities, gastrointestinal reactions, and liver enzyme abnormalities. Only 1 patient experienced a grade 3 gastrointestinal event.

CONCLUSIONS:

Pemetrexed maintenance chemotherapy can improve PFS in patients with advanced nonsquamous NSCLC with good tolerability.

• Authors: Jianjie Li, Yujia Chi, Guang Cao, Jun Zhao, Tongtong An, Meina Wu, Yuyan Wang, Minglei Zhuo, Xue Yang, Bo Jia, Hanxiao Chen, Jingjing Wang, Xiaoyu Zhai, Ziping Wang
• Journal: Journal of thoracic disease (J Thorac Dis) Vol. 13 Issue 3 Pg. 1813-1821 (Mar 2021) ISSN: 2072-1439 [Print] China
• PMID: 33841970 (Publication Type: Journal Article)
• Copyright: 2021 Journal of Thoracic Disease. All rights reserved.